Iridex Corp (NASDAQ: IRIX)

IRIDEX Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight threatening eye conditions, including glaucoma and retinal diseases. The company’s proprietary MicroPulse® Technology and Endpoint Management™ Technology are offered as optional treatment modes in select laser consoles alongside the standard continuous wave mode, allowing low energy, subvisible, tissue sparing laser therapy. Its product portfolio consists of laser consoles, delivery devices and single use disposable probes that address glaucoma, medical retina and surgical retina indications. IRIDEX designs its systems to be compatible with a range of diagnostic tools such as slit lamp adapters, indirect ophthalmoscopes and scanning delivery systems, enabling physicians to tailor treatment to specific clinical needs.

IRIDEX generates revenue primarily from the sale of its laser systems, delivery devices and consumable probes, as well as from repair, service and extended service contracts for its equipment. In fiscal year 2025 the company recorded total revenues of $52.7 million, compared with $48.7 million in fiscal year 2024. Revenue is derived from direct sales in the United States and Germany and through independent distributors in other international markets, including Italy, the United Kingdom, India and various smaller territories. The company’s consumable business, which comprises single use laser probe devices, provides a recurring revenue stream that complements the capital equipment sales of its laser consoles.

Within the ophthalmic laser market IRIDEX competes against established players such as Alcon Inc., Bausch Health Companies Inc., Carl Zeiss Meditec AG, Lumenis Ltd., Nidek Co. Ltd., Lumibird, ARC GmbH, Meridian, OD OS GmbH and Norlase. The company also faces competition from alternative glaucoma surgical device makers including Glaukos Corporation, Sight Sciences and New World Medical, Inc., as well as pharmaceutical firms such as Alcon, Inc., Allergan, Inc., Astellas Pharma Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc. and Roche Holding Ltd. IRIDEX’s competitive advantage stems from its proprietary MicroPulse and Endpoint Management technologies, which deliver a safer, tissue sparing alternative to conventional high energy continuous wave laser treatments while maintaining comparable clinical efficacy. These technologies enable precise thermal control, reduce the risk of collateral tissue damage and support repeatable procedures that do not compromise future interventions. In addition, IRIDEX benefits from a strong intellectual property portfolio, with 67 active U. S. patents and 94 active international patents covering its laser systems, delivery devices and associated methodologies.

IRIDEX serves ophthalmologists who treat glaucoma, retinal and pediatric eye diseases, as well as hospitals, ambulatory surgical centers, office clinics, research and teaching hospitals, government installations and veterinary practices. The company’s customers are located across the United States, Germany and other international regions including Europe, Asia, the Pacific Rim, the Middle East, Africa, Canada and Latin America. In the United States and Germany IRIDEX relies on a direct sales force, whereas in the remainder of its international footprint it works through independent distributors such as Topcon Corporation. The installed base of IRIDEX laser systems is supported by a global service network that provides depot repair, technical assistance and loaner equipment under warranty or service contracts.